TY - JOUR
T1 - Sarcopenia with limited mobility: an international consensus
AU - Society on Sarcopenia, Cachexia and Wasting Disorders Trialist Workshop
AU - Morley, John E
AU - Abbatecola, Angela Marie
AU - Argiles, Josep M
AU - Baracos, Vickie
AU - Bauer, Juergen
AU - Bhasin, Shalender
AU - Cederholm, Tommy
AU - Coats, Andrew J Stewart
AU - Cummings, Steven R
AU - Evans, William J
AU - Fearon, Kenneth
AU - Ferrucci, Luigi
AU - Fielding, Roger A
AU - Guralnik, Jack M
AU - Harris, Tamara B
AU - Inui, Akio
AU - Kalantar-Zadeh, Kamyar
AU - Kirwan, Bridget-Anne
AU - Mantovani, Giovanni
AU - Muscaritoli, Maurizio
AU - Newman, Anne B
AU - Rossi-Fanelli, Filippo
AU - Rosano, Giuseppe M C
AU - Roubenoff, Ronenn
AU - Schambelan, Morris
AU - Sokol, Gerald H
AU - Storer, Thomas W
AU - Vellas, Bruno
AU - von Haehling, Stephan
AU - Yeh, Shing-Shing
AU - Anker, Stefan D
N1 - Copyright © 2011 American Medical Directors Association. Published by Elsevier Inc. All rights reserved.
PY - 2011
Y1 - 2011
N2 - A consensus conference convened by the Society of Sarcopenia, Cachexia and Wasting Disorders has concluded that "Sarcopenia, ie, reduced muscle mass, with limited mobility" should be considered an important clinical entity and that most older persons should be screened for this condition. "Sarcopenia with limited mobility" is defined as a person with muscle loss whose walking speed is equal to or less than 1 m/s or who walks less than 400 m during a 6-minute walk, and who has a lean appendicular mass corrected for height squared of 2 standard deviations or more below the mean of healthy persons between 20 and 30 years of age of the same ethnic group. The limitation in mobility should not clearly be a result of otherwise defined specific diseases of muscle, peripheral vascular disease with intermittent claudication, central and peripheral nervous system disorders, or cachexia. Clinically significant interventions are defined as an increase in the 6-minute walk of at least 50 meters or an increase of walking speed of at least 0.1 m/s.
AB - A consensus conference convened by the Society of Sarcopenia, Cachexia and Wasting Disorders has concluded that "Sarcopenia, ie, reduced muscle mass, with limited mobility" should be considered an important clinical entity and that most older persons should be screened for this condition. "Sarcopenia with limited mobility" is defined as a person with muscle loss whose walking speed is equal to or less than 1 m/s or who walks less than 400 m during a 6-minute walk, and who has a lean appendicular mass corrected for height squared of 2 standard deviations or more below the mean of healthy persons between 20 and 30 years of age of the same ethnic group. The limitation in mobility should not clearly be a result of otherwise defined specific diseases of muscle, peripheral vascular disease with intermittent claudication, central and peripheral nervous system disorders, or cachexia. Clinically significant interventions are defined as an increase in the 6-minute walk of at least 50 meters or an increase of walking speed of at least 0.1 m/s.
KW - Aged
KW - Consensus
KW - Female
KW - Humans
KW - Internationality
KW - Male
KW - Middle Aged
KW - Mobility Limitation
KW - Muscle, Skeletal
KW - Sarcopenia
UR - http://www.scopus.com/inward/record.url?scp=79959617857&partnerID=8YFLogxK
U2 - 10.1016/j.jamda.2011.04.014
DO - 10.1016/j.jamda.2011.04.014
M3 - Article
C2 - 21640657
SN - 1538-9375
VL - 12
SP - 403
EP - 409
JO - Journal of the American Medical Directors Association
JF - Journal of the American Medical Directors Association
IS - 6
ER -